AMadison nonprofit started by the head of Promega Corp. is resuming a study of psilocybin, the hallucinogenic ingredient in “magic mushrooms,” to treat depression at UW-Madison and six other sites after the COVID-19 pandemic halted the research.
AMadison nonprofit started by the head of Promega Corp. is resuming a study of psilocybin, the hallucinogenic ingredient in “magic mushrooms,” to treat depression at UW-Madison and six other sites after the COVID-19 pandemic halted the research.